Subtype
Intracranial Neoplasm
CI-CAN-00001030Explore in graph →
Non-malignant522 active trials34 evidence items
- NCIt
- C4953
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001030Explore in graph →
Clinical trials
2,178 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01128218 | A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 33 | Southern Illinois UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05812534 | Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases(CBC) | unknown | Phase 2 | 36 | Second Affiliated Hospital of Nanchang UniversityOTHER |
| 0 |
| Nov 18, 2023 |
| clinicaltrials |
| NCT03951142 | Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study(ImPRESS) | unknown | Phase 2 | 165 | Kyrre Eeg EmblemOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT01508221 | Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis | completed | Phase 2 | 31 | University of CincinnatiOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT03430947 | Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases(RadioCoBRIM) | terminated | Phase 2 | 20 | Technische Universität DresdenOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT00659126 | Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors | terminated | Phase 2 | 40 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT04427228 | Single vs Multi-fraction SRS Patients on Immunotherapy(MIGRAINE) | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03520842 | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04659421 | Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas | completed | Phase 2 | 60 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT01689727 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors | completed | Phase 2 | 40 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT01188096 | A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas(Poly-ICLC) | completed | Phase 2 | 23 | Wake Forest University Health SciencesOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT02879682 | nTMS for Motor Mapping of Rolandic Lesions(Motorstim) | completed | Phase 2 / Phase 3 | 330 | Technical University of MunichOTHER | 3 | Jun 1, 2023 | clinicaltrials |
| NCT00187226 | A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects | completed | Phase 2 | 361 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT04507217 | Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC | completed | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT02137759 | MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | unknown | Phase 2 | 29 | Emory UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03436433 | Seizure Prophylaxis in Patients With Glioma or Brain Metastasis | terminated | Phase 2 | 4 | Duke UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT00582075 | Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases(RAD0102) | completed | Phase 2 | 25 | University of Alabama at BirminghamOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT02490878 | Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases | terminated | Phase 2 | 19 | Alliance for Clinical Trials in OncologyOTHER | 2 | Mar 23, 2023 | clinicaltrials |
| NCT04650490 | SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer(STICk-IM-NSCLC) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02017964 | Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma | completed | Phase 2 | 26 | Children's Oncology GroupNETWORK | 4 | Jan 9, 2023 | clinicaltrials |
| NCT00312728 | A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) | completed | Phase 2 | 115 | Genentech, Inc.INDUSTRY | 0 | Jan 6, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT00659334 | Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation | terminated | Phase 2 | 116 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT04211090 | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC(CAP-BRAIN) | unknown | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT04597801 | Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation(INVIVO) | completed | Phase 2 | 210 | Technical University of MunichOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02115139 | GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases(GRAY-B) | completed | Phase 2 | 58 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03668847 | DM-CHOC-PEN for Brain Tumors in AYA Subjects | completed | Phase 2 | 20 | DEKK-TEC, Inc.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01469247 | Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT) | completed | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02885324 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | terminated | Phase 2 | 4 | Indiana UniversityOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02849743 | Intranasal Oxytocin in Hypothalamic Obesity | completed | Phase 2 | 18 | Shana McCormack, MDOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT03352427 | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations | terminated | Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02302235 | Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study(GBMXRT) | completed | Phase 2 | 42 | Mid-Atlantic Epilepsy and Sleep Center, LLCOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03930771 | Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas(TMZ-Cap) | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05084092 | IORT After Surgical Resection of Brain Metastases(IORT_BRAINM1) | unknown | Phase 2 | 40 | Institut Català d'OncologiaOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02881957 | Hypovitaminosis D in Neurocritical Patients | completed | Phase 2 / Phase 3 | 274 | University of UtahOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT01434602 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02750891 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | completed | Phase 1 / Phase 2 | 18 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04863339 | Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery | withdrawn | Phase 2 | 0 | University of North Carolina, Chapel HillOTHER | 0 | Apr 5, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 30, 2023source: clinicaltrials